---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003859"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:29:29.386713+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine discloses ITGC material weakness; outlines bitopertin NDA plan and 2025 milestones

## Summary
- Material weakness in ITGC over key financial IT systems; no misstatements identified to date.
- Bitopertin NDA submission plans to be discussed after Type C FDA meeting in Q1 2025; potential accelerated approval for EPP.
- Initial phase 2 data for DISC-0974 in myelofibrosis anemia expected H2 2025; multiple-dose CKD data also H2 2025.
- Phase 2 trial of DISC-3405 in polycythemia vera planned to start H1 2025.

## SEC filing metadata
- accession: 0000950170-25-003859
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/0000950170-25-003859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003859
- JSON: https://secwatch.observer/filing/0000950170-25-003859.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.